

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
**WO 2004/010997 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/428.** (US). SKOUG, Connie, J. [US/US]; 9942 Wexford Drive, Portage, MI 49024 (US).

(21) International Application Number:  
PCT/US2003/023205

(74) Agents: FORBES, James, C. et al.; Pharmacia Corporation, 575 Maryville Centre Drive, 5th Floor Mail Zone 1006, St. Louis, MO 63141 (US).

(22) International Filing Date: 25 July 2003 (25.07.2003)

(81) Designated States (*national*): AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/398,427	25 July 2002 (25.07.2002)	US
60/398,447	25 July 2002 (25.07.2002)	US
60/479,513	18 June 2003 (18.06.2003)	US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, BE, ES, FI, FR, GB, GR, HU, IE, IT, LI, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): PHARMACIA CORPORATION [US/US]; Global Patent Department, 575 Maryville Centre Drive-5th Floor, Mail Zone 1006, St. Louis, MO 63141 (US).

(72) Inventors; and

(73) Inventors/Applicants (*for US only*): AMIDON, Gregory, E. [US/US]; 7174 Hickory Point Drive, Portage, MI 49024 (US). GANORKAR, Loksiddh, D. [MU/US]; 5307 Willowbend Trail, Kalamazoo, MI 49009 (US). HEIMLICH, John, M. [US/US]; 1665 Auburn Woods Trail, Portage, MI 49002 (US). LEE, Ernest, J. [US/US]; 5250 Colony Woods Drive, Kalamazoo, MI 49009 (US). NOACK, Robert, M. [US/US]; 1134 Iroquois Drive, S.E., Grand Rapids, MI 49506 (US). REO, Joseph, P. [US/US]; 5914 Bluejay Drive, Kalamazoo, MI 49009

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUSTAINED-RELEASE TABLE COMPOSITION OF PRAMIPEXOLE

(57) Abstract: A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm<sup>-2</sup> at a solid fraction representative of a tablet.

WO 2004/010997 A1

## SUSTAINED-RELEASE TABLET COMPOSITION OF PRAMIPEXOLE

### FIELD OF THE INVENTION


**[0001]** The present invention relates to tablet formulations, and more particularly to a sustained-release tablet composition for oral delivery of a water-soluble drug or prodrug, exemplified by pramipexole dihydrochloride.

### BACKGROUND OF THE INVENTION

**[0002]** Many active pharmaceutical agents, including drugs and prodrugs, have been formulated as orally deliverable dosage forms providing sustained release (otherwise known as slow release or extended release) of such agents over a period of time effective to permit once daily administration. A well-known system for formulating such dosage forms involves a matrix comprising a hydrophilic polymer wherein the agent is dispersed; the agent is released over a period of time in the gastrointestinal tract upon dissolution or erosion of the matrix. Sustained-release dosage forms comprising such a matrix system are conveniently prepared as compressed tablets, described herein as "matrix tablets".

**[0003]** Drugs and prodrugs having relatively high solubility in water, for example a solubility of about 10 mg/ml or greater, present challenges to the formulator wishing to provide a sustained-release dosage form, and the higher the solubility the greater are the challenges. These challenges are well illustrated in the cases of pramipexole dihydrochloride, which has a solubility in water of about 200 mg/ml.

**[0004]** Pramipexole (I) is a dopamine D<sub>2</sub> receptor agonist useful in treatment of Parkinson's disease. Pramipexole as its dihydrochloride salt is commercially available in the United States as Mirapex® tablets of Pharmacia & Upjohn. These are immediate-release tablets in 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg and 1.5 mg strengths, designed for oral administration of a single tablet three times per day to provide a daily dose of 0.375 to 4.5 mg. See *Physicians' Desk Reference* 57th edition (2003), 2768–2772. Doses herein are expressed in amounts of pramipexole dihydrochloride monohydrate unless otherwise specified; 1.0 mg pramipexole dihydrochloride monohydrate is equivalent to about 0.7 mg pramipexole base.



**[0005]** A three times daily dosing regimen for immediate-release pramipexole

dihydrochloride tablets is well tolerated, but patient compliance would be much improved if a once-daily regimen were possible. In this regard, it will be noted that the primary indication for the drug, Parkinson's disease, is an affliction that becomes more prevalent with advancing age and is often accompanied by decline in memory. A once-daily regimen would be especially useful in enhancing compliance among elderly patients.

[0006] It has been found by the present inventors that formulation of pramipexole dihydrochloride in a hydrophilic matrix tablet is generally inadequate to provide sustained-release properties consistent with once-daily dosing. Release characteristics can be further modified by coating the tablet with a sustained-release coating. Such a coating typically comprises a hydrophobic polymer and a hydrophilic pore-former.

[0007] The need to provide a coating over the matrix tablet gives rise to further problems. The additional handling operations involved in a coating step require a sufficient degree of tablet hardness to avoid tablet breakage and/or attrition during these operations, particularly in a high-speed manufacturing situation.

[0008] It has proved difficult to formulate a tablet having a suitable combination of sustained-release and handling properties, where the drug is one having relatively high solubility, as in the case of pramipexole dihydrochloride.

[0009] U.S. Patent No. 6,197,339 discloses a sustained-release tablet comprising (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) (sumanoreole maleate) in a matrix comprising hydroxypropylmethylcellulose (HPMC) and starch. The tablet is disclosed to be useful in treatment of Parkinson's disease. Starches disclosed to be suitable therein include pregelatinized starch.

[0010] U.S. Patent No. 5,458,887 discloses a controlled-release tablet comprising an osmotic core that consists of a drug in admixture with a water-swellable component such as HPMC or polyethylene oxide, and a coating that comprises a water-resistant polymer and a minor amount of a water-soluble compound that acts as a pore-former. Upon formation of pores in the coating by dissolution of the water-soluble compound, the water-swellable agent is said to expand the core and provide a drug-rich surface in contact with gastrointestinal fluid.

[0011] U.S. Patent No. 5,656,296 discloses a dual control sustained-release formulation comprising a core that comprises a drug and a low melting point excipient, and a coating layer over the core that comprises a pH-independent water-insoluble polymer and a water-soluble film-forming polymer.

[0012] European Patent Application No. EP 0 933 079 discloses a starch said to be suitable for preparing tablets having high hardness yet being capable of rapid disintegration in an aqueous medium. Tensile strength of the finished tablets is calculated from the hardness.

[0013] Patents and publications cited above are incorporated herein by reference.

[0014] It is an object of the present invention to provide a sustained-release tablet composition of a water-soluble salt of pramipexole that is suitable for once-daily oral administration. It is a further object to provide such a composition having sufficient hardness to withstand a high-speed tabletting operation, in particular to resist erosion during application of a coating layer. It is a further object to provide a pharmaceutical tablet comprising a water-soluble salt of pramipexole that provides day-long therapeutic effect when administered once daily, without substantially increased incidence of adverse side effects.

#### SUMMARY OF THE INVENTION

[0015] There is now provided a sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprising a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about  $0.15 \text{ kN cm}^{-2}$  at a solid fraction representative of the tablet. The composition preferably exhibits sustained-release properties adequate to provide therapeutic effectiveness when administered orally not more than once daily to a subject in need thereof.

[0016] There is further provided a method of treatment of a subject having a condition or disorder for which a dopamine D<sub>2</sub> receptor agonist is indicated, the method comprising orally administering to the subject a sustained-release pharmaceutical composition in a form of a tablet comprising a water-soluble salt of pramipexole dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about  $0.15 \text{ kN cm}^{-2}$  at a solid fraction representative of the tablet.

[0017] The term "water-soluble" herein means having solubility of at least about 10 mg/ml. Unless otherwise specified, "solubility" herein means solubility in water at 20–25°C at any physiologically acceptable pH, for example at any pH in the range of about 4 to about 8. In the case of a salt, reference herein to solubility in water pertains to the salt, not to the free base form of pramipexole.

[0018] "Solid fraction" is the ratio of absolute to apparent density of a compact of the

starch. A "compact" herein is a compressed tablet, prepared for example on a tablet press, consisting only of a sample of starch for which it is desired to measure tensile strength. A "solid fraction representative of the tablet" is a solid fraction selected to be similar to the solid fraction of tablets prepared according to the invention. Typically a solid fraction of about 0.75 to about 0.85, illustratively 0.8, will be selected.

[0019] The term "orally deliverable" herein means suitable for oral, including peroral and intra-oral (e.g., sublingual or buccal) administration, but tablets of the present invention are adapted primarily for peroral administration, i.e., for swallowing, typically whole or broken, with the aid of water or other drinkable fluid.

[0020] A "subject" herein is an animal of any species, preferably mammalian, most preferably human. Conditions and disorders in a subject for which a particular agent is said herein to be "indicated" are not restricted to conditions and disorders for which the agent has been expressly approved by a regulatory authority, but also include other conditions and disorders known or believed by a physician to be amenable to treatment with the agent. "Treatment" herein embraces prophylactic treatment unless the context requires otherwise.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Fig. 1 is a graph showing relationship of tensile strength of pregelatinized starch lots, as determined by a test method of the invention using a 4 second dwell time (Example 1 herein) to triaxial tensile strength.

[0022] Fig. 2 is a graph showing relationship of tensile strength of pregelatinized starch lots, as determined by a test method of the invention using a 90 second dwell time (Example 1 herein) to triaxial tensile strength.

[0023] Fig. 3 is a graph showing correlation of tensile strength of pregelatinized starch lots with maximum hardness of tablets containing these lots.

[0024] Fig. 4 is a graph showing *in vitro* dissolution profiles of three different 0.375 mg sustained-release tablet formulations of pramipexole dihydrochloride monohydrate, as more fully described in Example 10.

[0025] Fig. 5 is a graph from a human PK study showing time course of mean plasma pramipexole concentration following oral administration of 0.375 mg pramipexole dihydrochloride, either as a 0.125 mg immediate-release tablets administered three times at 8-hour intervals or as a single 0.375 mg dose of each of three different sustained-release tablets, as more fully described in Example 10.

[0026] Fig. 6 shows *in vitro/in vivo* correlation for the 0.375 mg pramipexole dihydrochloride tablets of Example 5.

[0027] Fig. 7 shows *in vitro/in vivo* correlation for the 0.375 mg pramipexole dihydrochloride tablets of Example 6.

[0028] Fig. 8 shows *in vitro/in vivo* correlation for the 0.375 mg pramipexole dihydrochloride tablets of Example 9.

#### DETAILED DESCRIPTION OF THE INVENTION

[0029] In one embodiment, the invention provides a pharmaceutical composition in a form of an orally deliverable tablet comprising a water-soluble salt of pramipexole.

[0030] Preferred salts have solubility not less than about 50 mg/ml, more preferably not less than about 100 mg/ml.

[0031] It will be understood that mention of pramipexole or a salt thereof herein embraces racemates, enantiomers, polymorphs, hydrates and solvates thereof.

[0032] Pramipexole (I) is used preferably in the form of its S-enantiomer, (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole. A preferred salt of pramipexole is the dihydrochloride salt, most preferably in the form of the monohydrate.

[0033] Pramipexole compositions of the invention are preferably suitable for administration no more than once daily. Such compositions are useful in treatment of any CNS condition or disorder for which pramipexole has therapeutic utility, but especially Parkinson's disease and complications associated therewith.

[0034] Pramipexole and its salts useful herein can be prepared by processes known *per se*, including processes disclosed in patents and other literature pertaining to pramipexole.

[0035] The amount of the pramipexole salt present in a composition of the invention is sufficient to provide a daily dose in one to a small plurality, for example one to about 4, of tablets to be administered at one time. Preferably the full daily dose is delivered in a single tablet.

[0036] An amount of pramipexole salt, expressed as pramipexole dihydrochloride monohydrate equivalent, of about 0.1 to about 10 mg per tablet, or about 0.05% to about 5% by weight of the composition, will generally be suitable. Preferably an amount of about 0.2 to about 6 mg, more preferably an amount of about 0.3 to about 5 mg, per tablet is present. Specific dosage amounts per tablet contemplated herein include 0.375, 0.5, 0.75, 1.0, 1.5, 3.0 and 4.5 mg pramipexole dihydrochloride monohydrate.

[0037] A composition of the present invention comprises a pramipexole salt as defined above, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm<sup>-2</sup> at a solid fraction representative of the tablet, for example about 0.75 to about 0.85, illustratively 0.8.

[0038] Hydrophilic polymers useful herein are pharmaceutically acceptable polymeric materials having a sufficient number and distribution of hydrophilic substituents such as hydroxy and carboxy groups to impart hydrophilic properties to the polymer as a whole. Suitable hydrophilic polymers include, without limitation, methylcellulose, HPMC (hypromellose), carmellose (carboxymethylcellulose) sodium and carbomer (polyacrylic acid). More than one such polymer can optionally be used.

[0039] HPMC is a preferred hydrophilic polymer. Various types and grades of HPMC are available. In one embodiment HPMC type 2208, preferably meeting specifications set forth in a standard pharmacopeia such as USP 24, is used. HPMC type 2208 contains 19-24% by weight methoxy and 4-12% by weight hydroxypropoxy substituents. Especially suitable HPMCs have nominal viscosity ranging from about 100 to about 10,000 mPa s; illustratively a suitable HPMC type 2208 is one having a nominal viscosity of about 4,000, with a measured viscosity of about 3,000 to about 5,600 mPa s. Such an HPMC is available, for example, as Methocel® K4MP from Dow Chemical Co., and substantially equivalent products are available from other manufacturers.

[0040] The amount of hydrophilic polymer in the composition depends on the particular polymer selected, on the active pharmaceutical agent and on the desired sustained release profile. Typically, however, the hydrophilic polymer is included in an amount of about 20% to about 70%, preferably about 30% to about 60% and more preferably about 35% to about 50%, by weight of the composition. In the illustrative case of HPMC type 2208, a suitable amount will generally be found in the range from about 30% to about 60%, preferably about 35% to about 50%, for example about 40%, by weight of the composition.

[0041] It is believed, without being bound by theory, that the hydrophilic polymer functions to provide extended or sustained release of the pramipexole, for example by gradual dissolution or erosion of the polymer in the gastrointestinal tract.

[0042] Starches useful herein include starches from any suitable botanical source, for example corn, wheat, rice, tapioca, potato, etc. Preferred starches have a relatively high ratio of amylose to amylopectin, containing for example at least about 20%, more

preferably at least about 25%, amylose. Especially preferred is pregelatinized starch, which is a type of modified starch that has been processed to render the starch more flowable and directly compressible. Partially or wholly pregelatinized starches can be used.

[0043] It is believed, without being bound by theory, that the primary function of the starch in a composition of the invention is as a binding agent. A starch meeting the tensile strength criterion defined herein can be referred to as a "super binder".

[0044] The amount of starch in the composition is typically higher than is conventionally present as a binder in tablet formulations. Suitable amounts will generally be found in the range of about 25% to about 75% by weight. Preferably the amount of starch is about 40% to about 70%, more preferably about 45% to about 65%, for example about 50%, by weight of the composition.

[0045] Tensile strength of a starch sample can be measured by any suitable test. Illustrative test procedures are described by Hiestand & Smith (1984), *Powder Technology* 38, 145-159, and by Hiestand & Smith (1991), *International Journal of Pharmaceutics* 67, 231-246, these articles being incorporated herein by reference.

[0046] An example of a tensile strength test that can be used (herein referred to as a "triaxial tensile strength test") requires preparation of a series of compacts of the starch sample, followed by determination of tensile strength of the compacts using a computerized multifunction tablet tester (MTT). The compacts are prepared with various degrees of compression force to provide compacts having a range of solid fraction. As a sustained release tablet formulation typically has a solid fraction of about 0.8, it is useful to prepare compacts approximating such a solid fraction.

[0047] Absolute density of the starch sample can be determined using a helium-air pycnometer.

[0048] A computer-controlled triaxial tablet press is used to prepare the compacts. Voltage output from the punch and die load cells of the tablet press are first zeroed. The punch and die are lubricated with magnesium stearate powder and the die assembly is placed in the press. Compression and decompression parameters are selected on the computer. The desired amount of starch to be compacted is weighed and poured into the die cavity. The resulting powder bed is leveled with a spatula. The punch is inserted into the die and the computer-controlled compression/decompression cycle is started.

[0049] Just prior to the end of the compression phase, thickness of the compact as

measured by LVDT (linear variable differential transformer) is recorded. At the end of the compression phase, the final compression force as measured by voltage of the punch load cell is recorded.

[0050] At the end of the decompression phase, the punch and die rams are retracted. The compact is removed from the die and inspected for defects, such as cracking or sticking. Cracking can be reduced by increasing decompression time. If the compact is free of defects, its length, width, thickness and weight are measured to enable calculation of apparent density. Solid fraction is calculated by dividing absolute density by apparent density.

[0051] In preparation of the MTT for tensile strength determination, a suitable software program is run. The platen is screwed to the load cell of the MTT and the tensile strength assembly is slid into the MTT opposite the platen. The load cell signal is monitored via the computer and the zero offset on the signal conditioner is adjusted to provide a positive baseline voltage as close as possible to zero. A forward velocity is selected that will generate a time constant of approximately 15 seconds (usually the velocity selected will be about 0.8 to about 1.2 mm s<sup>-1</sup>).

[0052] The compact to be tested is placed in the holder of the tensile strength assembly. The motor is initiated via the computer, driving the platen toward the compact until the surface of the compact is detected, and stopping the platen a few millimeters from the compact. The oscilloscope is triggered, to record the force applied to the compact, and the motor is restarted. The platen is driven into the compact until a crack is detected, either by sight or by sound, and the motor is immediately reversed.

[0053] Peak force is recorded from the oscilloscope trace. Tensile strength is calculated from the peak force using appropriate computer software.

[0054] From several runs using compacts at a range of solid fractions around 0.8, data are plotted and tensile strength at a solid fraction of 0.8 is estimated. If the tensile strength at a solid fraction of 0.8 is about 0.15 kN cm<sup>-2</sup> or greater, the starch sample is deemed to be suitable for use in preparing a composition according to the invention.

[0055] It has now surprisingly been discovered that a much simpler test, one that is more amenable to implementation in a manufacturing setting, can be used to estimate tensile strength of a starch sample, in particular to determine whether the starch sample has a tensile strength of at least about 0.15 kN cm<sup>-2</sup> at a solid fraction representative of a desired sustained-release tablet.

[0056] According to this test, compacts of the starch sample are prepared on a standard automated tablet press under a range of compression forces. For example, a Carver press (e.g., Model 3888.1DT0000) fitted with flat-faced tooling of suitable diameter (e.g., 10/32 inch or about 0.7 cm for a 300 mg compact), operated at compression forces of about 4 to about 16 kN (about 900 to about 3600 lbf) for a dwell time of at least about 4 seconds has been found to give satisfactory results. Illustratively, such compacts can be prepared at 1000, 1500, 2000 and 3000 lbf (4.45, 6.67, 8.90 and 13.34 kN). Preferably a dwell time of at least about 10 seconds, more preferably at least about 30 seconds, still more preferably at least about 60 seconds, is used. Illustratively, a dwell time of 90 seconds has been found to give satisfactory results. Weight, diameter and thickness of each compact are measured accurately (alternatively, diameter can be assumed to equal that of the tooling) to enable calculation of apparent density and hence solid fraction, absolute density having been measured as described above, for example by helium-air pycnometry.

[0057] Hardness of each compact thus prepared is then determined by any suitable tablet hardness test, for example using a Key HT 500 hardness tester. Hardness is a measure of the force required to cause crushing of the compact, and is typically expressed in units such as kiloponds (kp) or Strong-Cobb units (SCU). A hardness of about 10.2 kp or about 14.4 SCU corresponds to a force of 0.1 kN.

[0058] For present purposes it is considered that crushing strength of the compact is equivalent to tensile strength. Thus tensile strength ( $\sigma_T$ , in  $\text{kN cm}^{-2}$ ) can be calculated from the equation

$$\sigma_T = 2F/\pi DH$$

where F is the force required to cause crushing (in kN), D is diameter of the compact (in cm) and H is thickness of the compact (in cm). For example, a compact of diameter 0.7 cm and thickness 0.4 cm having a hardness of 20 SCU (equivalent to a force of 0.139 kN) has a calculated tensile strength of  $0.316 \text{ kN cm}^{-2}$ .

[0059] The relationship between tensile strength and solid fraction is next established for the starch sample. This can be done by plotting data for tensile strength and solid fraction on a graph (solid fraction tends to increase with increasing compression force during preparation of the compact) or by performing a regression analysis. From that relationship, tensile strength at a standardized value of solid fraction can be estimated. The standardized value selected is one that is representative of the solid fraction of a

desired sustained-release tablet, *e.g.*, 0.8.

[0060] Where the material of the compact is pregelatinized starch, it has been found that tensile strength as determined in a simple test as described immediately above is surprisingly close to a "true" tensile strength measurement as determined by the triaxial tensile strength test method previously described, which in turn is essentially similar to methods known in the art such as that disclosed by Hiestand & Smith (1984), *op. cit.*

[0061] It has also been found that a longer dwell time (*e.g.*, 90 seconds) in the test method of the present invention gives a better correlation with triaxial tensile strength than a very short dwell time (*e.g.*, 4 seconds). See Example 1 below and Figs. 1 and 2.

[0062] An especially preferred starch has a tensile strength of at least about 0.175 kN cm<sup>-2</sup>, even more preferably at least about 0.2 kN cm<sup>-2</sup>, at a solid fraction representative of a desired sustained-release tablet.

[0063] Even among commercially available pregelatinized starches, the preferred type of starch for use in a composition of the invention, considerable variation exists in tensile strength. Pregelatinized starches not meeting the tensile strength criterion established herein are not readily identified without testing, for example by a method as disclosed above. Such pregelatinized starches are generally unsuitable for commercial-scale manufacture of a sustained-release matrix tablet formulation of a water-soluble drug or prodrug, because of a problem as set forth immediately below.

[0064] An uncoated tablet, or a tablet core prior to coating, comprising starch and a hydrophilic polymer acting as a matrix for a water-soluble drug or prodrug requires to have a certain minimum hardness in order to be able to resist breakage and/or attrition due to mechanical stresses imposed during a high-speed tabletting operation (including all steps up to and including filling of the tablets into containers). The minimum acceptable hardness will depend on a number of factors, including the severity of the mechanical stresses, but is typically at least about 20 SCU, preferably at least about 22 SCU, more preferably at least about 24 SCU (about 17 kp).

[0065] Hardness can be increased by increasing the compression force applied by the tablet press, but only up to a certain level. At least in the case of tablets as described herein, above a certain compression force, further increases in compression force give little or no further increase in tablet hardness. There is, in other words, a maximum hardness achievable by compression of a particular starch/hydrophilic polymer/active agent composition. A starch providing a maximum hardness inadequate to withstand the

mechanical stresses of a high-speed tableting operation is unsuitable for the present purpose. As shown in Fig. 3, certain pregelatinized starches have been found to provide a maximum hardness of 20 SCU or less; these are now identified as starches having low tensile strength ( $0.1 \text{ kN cm}^{-2}$  or less according to the test method of the invention utilizing a dwell time of 90 seconds).

[0066] Even if a maximum hardness of at least about 20 SCU is achievable, with a starch of low tensile strength it may be achievable only by use of extremely high compression forces. A requirement for such forces reduces speed and efficiency and increases cost of a tableting operation and is undesirable for these reasons.

[0067] Where tablets are to be subjected to an additional process step after compression, in particular a coating step, exposure to mechanical stresses is greatly increased. According to a preferred embodiment, therefore, the sustained-release tablet of the invention further comprises a coating.

[0068] For pramipexole salts of high water solubility as specified herein, a hydrophilic polymer matrix can be inadequate to provide sustained release of sufficiently long duration to permit once daily administration. It is believed that such salts are readily leached out of the hydrophilic matrix when contacted by an aqueous medium such as gastrointestinal fluid. It is therefore desirable to further slow the process of drug release by providing a release-controlling coating around the tablet. Such a coating typically comprises a hydrophobic or water-insoluble polymer component such as ethylcellulose together with a hydrophilic or water-soluble pore-forming component such as HPMC.

[0069] Where a starch is used having a tensile strength of at least about  $0.15 \text{ kN cm}^{-2}$ , preferably at least about  $0.175 \text{ kN cm}^{-2}$ , more preferably at least about  $0.2 \text{ kN cm}^{-2}$ , at a solid fraction representative of the tablet (e.g., about 0.75 to about 0.85), the composition is found to be especially suited to a high-speed tableting operation that includes a step of coating the tablet with a release-controlling layer.

[0070] Alternatives to ethylcellulose and HPMC as components of a release coating layer include other cellulosic polymers (e.g., methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose sodium, cellulose esters such as cellulose acetate, etc.), polyvinyl acetate, polyvinyl pyrrolidone, polymers and copolymers of acrylic acid and methacrylic acid and esters thereof, polyethylene glycol, carrageenan and other gums, and the like.

[0071] A release-controlling layer, if present, typically constitutes about 1% to about

15%, preferably about 2.5% to about 10%, by weight of the tablet as a whole. The hydrophobic or water-insoluble component, preferably comprising ethylcellulose, typically constitutes about 1% to about 10%, preferably about 2% to about 7%, by weight of the tablet as a whole. The pore-forming component, preferably comprising HPMC, is typically present in an amount of about 5% to about 50%, preferably about 10% to about 40%, by weight of the water-insoluble or hydrophobic component.

[0072] The coating, if present, can optionally contain additional pharmaceutically acceptable excipients such as plasticizers, dyes, *etc.*

[0073] Illustratively, a release-controlling layer in an amount of about 2.5% to about 5% by weight of the tablet core (*i.e.*, the tablet weight excluding the coating) comprises an ethylcellulose-based material (*e.g.*, Surelease® of Colorcon) and an HPMC-based pore-forming material (*e.g.*, Opadry® of Colorcon) in a weight ratio of about 3:1 to about 4:1.

[0074] A release-controlling layer or coating should be applied at as uniform a thickness as possible to provide optimum control of release rate of the pramipexole.

[0075] Alternatively or in addition, the sustained-release tablet of the invention comprises a nonfunctional coating. A nonfunctional coating can comprise a polymer component, for example HPMC, optionally with other ingredients, for example one or more plasticizers, colorants, *etc.* The term "nonfunctional" in the present context means having no substantial effect on release properties of the tablet, and does not imply that the coating serves no useful purpose. For example, such a coating can impart a distinctive appearance to the tablet, provide protection against attrition during packaging and transportation, improve ease of swallowing, and/or have other benefits. A nonfunctional coating should be applied in an amount sufficient to provide complete coverage of the tablet. Typically an amount of about 1% to about 10%, more typically an amount of about 2.5% to about 5%, by weight of the tablet as a whole, will be found suitable.

[0076] Uncoated tablets and cores of coated tablets of the invention can optionally contain one or more pharmaceutically acceptable excipients in addition to the starch and hydrophilic polymer components described above. Such excipients include without limitation glidants and lubricants. Other conventional excipients known in the art can also be included.

[0077] A glidant can be used to improve powder flow properties prior to and during tableting and to reduce caking. Suitable glidants include colloidal silicon dioxide,

magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate and the like. In one embodiment, colloidal silicon dioxide is included as a glidant in an amount up to about 2%, preferably about 0.2% to about 0.6%, by weight of the tablet.

[0078] A lubricant can be used to enhance release of a tablet from apparatus on which it is formed, for example by preventing adherence to the face of an upper punch ("picking") or lower punch ("sticking"). Suitable lubricants include magnesium stearate, calcium stearate, canola oil, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, mineral oil, poloxamer, polyethylene glycol, polyvinyl alcohol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, hydrogenated vegetable oil, zinc stearate and the like. In one embodiment, magnesium stearate is included as a lubricant in an amount of about 0.1% to about 1.5%, preferably about 0.3% to about 1%, by weight of the tablet.

[0079] Tablets can be of any suitable size and shape, for example round, oval, polygonal or pillow-shaped, and optionally bear nonfunctional surface markings. Especially in the case of coated tablets they are preferably designed to be swallowed whole and are therefore typically not provided with a breaking score. Tablets of the invention can be packaged in a container, accompanied by a package insert providing pertinent information such as, for example, dosage and administration information, contraindications, precautions, drug interactions and adverse reactions.

[0080] There is also provided a method of treatment of a subject having a condition or disorder for which a dopamine D<sub>2</sub> receptor agonist is indicated, the method comprising orally administering to the subject a sustained-release pharmaceutical composition in a form of a tablet comprising a water-soluble salt of pramipexole dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm<sup>-2</sup> at a solid fraction representative of the tablet. Preferably the composition is administered no more than once daily.

[0081] In a particular embodiment, the condition or disorder is Parkinson's disease or a complication associated therewith.

[0082] Suitable daily dosage amounts include 0.375, 0.5, 0.75, 1.0, 1.5, 3.0 and 4.5 mg pramipexole dihydrochloride monohydrate.

[0083] In a further embodiment, a composition of the invention is administered in combination therapy with one or more additional drugs or prodrugs. The term "combination therapy" herein means a treatment regimen wherein the agent provided by

the composition of the invention and a second agent are administered individually or together, sequentially or simultaneously, in such a way as to provide a beneficial effect from co-action of these therapeutic agents. Such beneficial effect can include, but is not limited to, pharmacokinetic or pharmacodynamic co-action of the therapeutic agents. Combination therapy can, for example, enable administration of a lower dose of one or both agents than would normally be administered during monotherapy, thus decreasing risk or incidence of adverse effects associated with higher doses. Alternatively, combination therapy can result in increased therapeutic effect at the normal dose of each agent in monotherapy. "Combination therapy" herein is not intended to encompass administration of two or more therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in sequential or simultaneous treatment.

[0084] Compositions of the invention can be especially suited to combination therapies, particularly where the second agent is one that is, or can be, administered once daily. There are significant advantages in patient convenience and compliance where both components of a combination therapy can be administered at the same time and with the same frequency. This is especially true in the case of geriatric patients or those suffering memory impairment.

[0085] When administered simultaneously, the two components of the combination therapy can be administered in separate dosage forms or in coformulation, *i.e.*, in a single dosage form. When administered sequentially or in separate dosage forms, the second agent can be administered by any suitable route and in any pharmaceutically acceptable dosage form, for example by a route and/or in a dosage form other than the present composition. In a preferred embodiment, both components of the combination therapy are formulated together in a single dosage form.

#### EXAMPLES

##### Example 1

[0086] Tensile strength of six commercially obtained lots of pregelatinized starch was determined using the triaxial tensile strength test procedure described hereinabove. Data for tensile strength at a solid fraction of 0.8 are presented in Table 1.

**Table 1. Tensile strength of pregelatinized starch lots at a solid fraction of 0.8  
(triaxial test procedure)**

Lot	Tensile strength (kN cm <sup>-2</sup> )
1	0.323
2	0.220
3	0.074
4	0.119
5	0.287
6	0.236

[0087] A great variation in tensile strength of pregelatinized starches was observed, ranging from 0.074 to 0.323 kN cm<sup>-2</sup>. Lots 3 and 4, exhibiting the lowest values of tensile strength, were from one manufacturer. Lots 1, 5 and 6, exhibiting the highest values of tensile strength, were from a second manufacturer. Lot 2, exhibiting an intermediate value of tensile strength, was from a third manufacturer.

**Example 2**

[0088] Tensile strength of the same six lots of pregelatinized starch was determined by the following simplified test procedure.

[0089] Compacts of each starch lot were prepared on a Carver press, Model 3888.1DT0000 fitted with 10/32 inch (0.7 cm) flat-faced tooling, at compression forces of 1000, 1500, 2000 and 3000 lbf (4.45, 6.67, 8.90 and 13.34 kN), for a dwell time of 4 seconds or 90 seconds. Compacts of an additional three lots of pregelatinized starch (Lots 7, 8 and 9), from the same manufacturer as Lots 3 and 4, were prepared using a dwell time of 90 seconds only. Weight and thickness of each compact was measured (diameter being equal to that of the tooling) to enable calculation of apparent density. Absolute density of each starch lot was measured by helium-air pycnometry. Solid fraction was calculated as the ratio of apparent to absolute density.

[0090] Hardness (force required to cause crushing) of each compact was determined using a Key HT 500 hardness tester. Tensile strength was calculated from this force and dimensions of the compact, using the equation

$$\sigma_T = 2F/\pi DH$$

as described hereinabove.

[0091] A regression analysis was performed to determine the relationship of tensile strength to solid fraction for each starch lot, and tensile strength at a standardized solid fraction of 0.8 was calculated. Data are presented in Table 2.

**Table 2. Tensile strength of pregelatinized starch lots at a solid fraction of 0.8  
(simplified test procedure of the invention)**

Lot	Tensile strength (kN cm <sup>-2</sup> )	
	4 s dwell time	90 s dwell time
1	0.310	0.306
2	0.227	0.191
3	0.092	0.085
4	0.134	0.096
5	0.316	0.277
6	0.333	0.242
7	n.d.	0.087
8	n.d.	0.088
9	n.d.	0.172

[0092] Correlation of tensile strength as measured in the simplified test using a 4 second dwell time (this Example) with tensile strength as measured by the triaxial test procedure of Example 1 is shown graphically in Fig. 1.

[0093] Correlation of tensile strength as measured in the simplified test using a 90 second dwell time (this Example) with tensile strength as measured by the triaxial test procedure of Example 1 is shown graphically in Fig. 2.

[0094] Both dwell times exhibited a strong correlation, but the correlation was especially close where the simplified test used a 90 second dwell time. It is concluded that the simplified test as herein described can be used to estimate tensile strength of a starch lot for the purpose of predicting whether that starch lot will be suitable for preparing a sustained-release tablet formulation of the present invention.

Example 3

[0095] Sumanirole maleate sustained-release tablets were prepared having the compositions shown in Table 3. Tablet strength in mg is expressed as sumanirole base.

**Table 3. Composition of sumanirole maleate tablets of Example 3**

Ingredient	Tablet strength (mg)							
	0.5	1	2	4	8	8	12	24
	Amount (% by weight)							
sumanirole maleate	0.23	0.45	0.9	1.8	3.6	3.6	5.4	10.9
HPMC type 2208, 4000 mPa s	35.00	35.00	35.0	35.0	35.0	35.0	35.0	35.0
pregelatinized starch	63.87	63.65	63.2	62.3	60.5	60.0	58.2	52.5
colloidal silicon dioxide	0.40	0.40	0.4	0.4	0.4	0.4	0.4	0.4
magnesium stearate	0.50	0.50	0.5	0.5	0.5	1.0	1.0	1.0

[0096] All ingredients except the lubricant (magnesium stearate) were screened to remove lumps and were blended thoroughly in a low-shear mixer operating at 24 rpm for 10–30 minutes. The lubricant was then screened into the mixer and the materials were blended for a further 2–5 minutes. The resulting lubricated mixture was compressed into 350 mg pillow-shaped tablets using a Kilian S100 tabletting machine.

Example 4

[0097] Tablets similar to those of Example 3 were prepared using pregelatinized starches of lots 1–6 as tested in Examples 1 and 2. Maximum hardness of the tablets obtainable with each pregelatinized starch lot was determined.

[0098] Maximum hardness was correlated with tensile strength of the pregelatinized starch lot used, as measured in the simplified test of Example 2 using a 90 second dwell time. Results are shown in Fig. 3. The correlation was substantially linear.

[0099] In subsequent tests, tablets of different hardness were used as cores for coating and were tested for resistance to erosion during a high-speed coating operation. Tablet cores having a hardness of at least about 24 SCU (about 17 kp) were found to have acceptable resistance to erosion. As shown in Fig. 3, this degree of hardness is achievable using pregelatinized starch having a tensile strength of at least about 0.175 kN cm<sup>2</sup>. Pregelatinized starches of Lots 3 and 4 were unsuitable, having tensile strength less than about 0.15 kN cm<sup>2</sup> and providing tablets having a maximum hardness no greater than about 20 SCU (about 14 kp).

Example 5

[0100] Pramipexole dihydrochloride sustained-release tablets were prepared having the compositions shown in Table 4.

Table 4. Composition of pramipexole dihydrochloride tablets of Example 5

Ingredient	Amount (mg)							
pramipexole dihydrochloride monohydrate	0.375	0.75	1.5	3.0	4.5	0.375	0.375	4.5
HPMC type 2208, 4000 mPa s	140.0	140.0	140.0	140.0	140.0	70.0	157.5	157.5
pregelatinized starch	206.5	206.1	205.4	203.9	202.4	101.5	189.0	184.9
colloidal silicon dioxide	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
magnesium stearate	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75
total	350	350	350	350	350	175	350	350

[0101] The tablets were prepared by the procedure described in Example 3, using pregelatinized starch having a tensile strength of at least about 0.175 kN cm<sup>2</sup>.

Example 6

[0102] Coated sustained-release tablets of pramipexole dihydrochloride were prepared having the composition shown in Table 5.

Table 5. Composition of coated tablets of Example 6

Ingredient	Amount (mg)
pramipexole dihydrochloride monohydrate	0.375
HPMC type 2208, 4000 mPa s	140.0
pregelatinized starch	206.5
colloidal silicon dioxide	1.4
magnesium stearate	1.75
total core	350
ethylcellulose-based coating material (Surelease®)	7.88
HPMC-based coating material (Opadry®)	2.63
total coating	10.5

[0103] Tablet cores were prepared exactly as in Example 5, using pregelatinized starch having a tensile strength of at least about 0.175 kN cm<sup>-2</sup>. A coating solution was prepared as follows. Opadry® HPMC-based material in an amount of 6.004 g was added to 106.682 g water and mixed for 45 minutes to provide an HPMC mixture. Next, 72.045 g Surelease® ethylcellulose-based material was added to the HPMC mixture and mixed for an additional 30 minutes to provide a coating solution.

[0104] The coating solution was applied to the tablet cores in an amount providing a 3% weight gain. The resulting coated tablets were cured using a 12 inch (about 30 cm) Vector LCDS or 24 inch (about 60 cm) Thomas Accela-Coata coating pan for about 15 minutes at a bed temperature of at least about 70°C. After curing, temperature was ramped down over a period of about 8 minutes to an exhaust temperature of about 45°C.

Example 7

[0105] Coated sustained-release tablets of pramipexole dihydrochloride were prepared having the composition shown in Table 6.

**Table 6. Composition of coated tablets of Example 7**

Ingredient	Amount (mg)
pramipexole dihydrochloride monohydrate	0.375
HPMC type 2208, 4000 mPa s	140.0
pregelatinized starch	206.5
colloidal silicon dioxide	1.4
magnesium stearate	1.75
total core	350
ethylcellulose-based coating material (Surelease®)	8.4
HPMC-based coating material (Opadry®)	2.1
total coating	10.5

[0106] Tablet cores were prepared exactly as in Example 5, using pregelatinized starch having a tensile strength of at least about 0.175 kN cm<sup>-2</sup>. A coating solution was prepared as follows. Opadry® HPMC-based material in an amount of 4.801 g was added to 103.041 g water and mixed for 45 minutes to provide an HPMC mixture. Next, 76.819 g Surelease® ethylcellulose-based material was added to the HPMC mixture and mixed for an additional 30 minutes to provide a coating solution.

[0107] Coating to a 3% weight gain and curing of the coated tablets were performed exactly as in Example 6.

#### Example 8

[0108] Coated sustained-release tablets of pramipexole dihydrochloride were prepared having the composition shown in Table 7.

**Table 7. Composition of coated tablets of Example 8**

Ingredient	Amount (mg)
pramipexole dihydrochloride monohydrate	0.375
HPMC type 2208, 4000 mPa s	140.0
pregelatinized starch	206.5
colloidal silicon dioxide	1.4
magnesium stearate	1.75
total core	350
ethylcellulose-based coating material (Surelease®)	13.13
HPMC-based coating material (Opadry®)	4.38
total coating	17.5

[0109] Tablet cores were prepared exactly as in Example 5, using pregelatinized starch having a tensile strength of at least about 0.175 kN cm<sup>-2</sup>. A coating solution was prepared as follows. Opadry® HPMC-based material in an amount of 10.003 g was added to 177.737 g water and mixed for 45 minutes to provide an HPMC mixture. Next,

120.03 g Surelease® ethylcellulose-based material was added to the HPMC mixture and mixed for an additional 30 minutes to provide a coating solution.

[0110] Coating to a 3% weight gain and curing of the coated tablets were performed exactly as in Example 6. After this first curing step, coating was repeated to provide a total tablet weight gain of about 5%, followed by curing for about 15 minutes at a bed temperature of at least about 70°C. After curing, temperature was ramped down over a period of about 8 minutes to an exhaust temperature of about 45°C.

Example 9

[0111] Coated sustained-release tablets of pramipexole dihydrochloride were prepared having the composition shown in Table 8.

**Table 8. Composition of coated tablets of Example 9**

Ingredient	Amount (mg)
pramipexole dihydrochloride monohydrate	0.375
HPMC type 2208, 4000 mPa s	140.0
pregelatinized starch	206.5
colloidal silicon dioxide	1.4
magnesium stearate	1.75
total core	350
ethylcellulose-based coating material (Surelease®)	14.0
HPMC-based coating material (Opadry®)	3.5
total coating	17.5

[0112] Tablet cores were prepared exactly as in Example 5, using pregelatinized starch having a tensile strength of at least about 0.175 kN cm<sup>-2</sup>. A coating solution was prepared as follows. Opadry® HPMC-based material in an amount of 8.002 g was added to 171.735 g water and mixed for 45 minutes to provide an HPMC mixture. Next, 128.032 g Surelease® ethylcellulose-based material was added to the HPMC mixture and mixed for an additional 30 minutes to provide a coating solution.

[0113] Coating to a 5% total weight gain and curing of the coated tablets were performed exactly as in Example 8.

Example 10

[0114] Dissolution profiles of the 0.375 mg pramipexole dihydrochloride tablets of each of Examples 5, 6 and 9 were evaluated in a standard *in vitro* USP dissolution assay under the following conditions. USP apparatus 1 was used to stir a dissolution medium (900 ml of 0.05M phosphate buffer at a pH of 6.8) at a spindle rotation speed of 100 rpm

and a temperature of 37°C.

[0115] Data are shown in Fig. 4. The uncoated tablet of Example 5 and the tablet of Example 6 having a 3% coating comprising 25% pore-former exhibited very similar overall dissolution profiles. On close inspection, however, it will be noticed that the uncoated tablet of Example 5 showed faster initial dissolution, such that at 1 hour and 2 hour sampling times the percent dissolved was greater, than in the case of the coated tablet of Example 6. For example, at 1 hour, the coated tablet of Example 6 showed only 11% dissolution, while the uncoated tablet of Example 5 showed 15% dissolution. Similarly, at 2 hours, the coated tablet of Example 6 showed no more than 20% dissolution, while the uncoated tablet of Example 5 showed 24% dissolution.

[0116] Dissolution of the tablet of Example 9 having a 5% coating comprising 20% pore-former exhibited a dissolution profile much slower than either the tablet of Example 5 or the tablet of Example 6.

#### Example 11

[0117] An *in vivo* study was conducted in healthy human volunteers to assess bioavailability of pramipexole formulated as the 0.375 mg sustained-release or extended-release (XR) tablets of Examples 5, 6 and 9 by comparison with a reference treatment with immediate-release (IR) pramipexole dihydrochloride tablets, and to evaluate safety of pramipexole when its absorption profile is altered as in these extended-release tablets.

#### Method

[0118] The study followed an open-label, 4-way, randomized crossover design and was conducted in healthy male and female subjects ranging from 18 to 55 years of age. The subjects received each of the four treatments during the course of the study, which was conducted at a single center. A total of 12 subjects were enrolled. The subjects were fasted overnight and then given a 0.375 mg oral dose of pramipexole dihydrochloride monohydrate. In the case of the IR formulation, which was provided as Mirapex® tablets, three equally divided doses of 0.125 mg each were given at 8-hour intervals, beginning in the morning. In the case of the XR formulations of Examples 5, 6 and 9, a single 0.375 mg tablet was given in the morning. Serial blood samples were taken over a 48-hour period for PK assessment. Adverse events were recorded during the same 48-hour period.

[0119] Plasma pramipexole concentrations were quantitated by an HPLC-MS/MS method, validated over the assay range 0.05–15 ng/ml. All runs met bioanalytical

acceptance criteria for calibration standards and quality control. Samples were not diluted prior to analysis as all sample concentrations were within the limits of quantitation.

[0120] PK parameters for pramipexole were estimated by non-compartmental methods, using the nonlinear regression program Kinetica of Innaphase. Individual plasma concentration data and the actual time-points of blood sampling from each subject were used in the analysis. Plasma concentrations below the lower limit of quantitation at early time-points were set to zero, whereas those in the terminal phase were excluded from the analysis.

[0121] *In vivo* pramipexole absorption data were derived by a deconvolution routine employing the Kinetica program. To perform this analysis, a fit of the pramipexole data from the reference treatment was first made to a one-compartment open PK disposition model with first order absorption. Based on this fit, plasma pramipexole concentrations were simulated for a 0.375 mg intravenous bolus dose of pramipexole. These simulated pramipexole concentrations were used in the deconvolution routine.

[0122] *In vitro/in vivo* correlations for each of the pramipexole XR formulations were examined by evaluating a linear relationship of *in vivo* absorption as a function of *in vitro* dissolution.

[0123] Prediction of mean steady-state concentrations arising from repeated daily dosing was performed by interpolation of hourly concentrations from individual subjects' observed concentration/time data and then by the principle of superposition, estimating the concentrations during the 6th day of dosing. Estimates of half-life obtained from this study, which were consistent with values reported previously, indicate that steady-state would be achieved by the 4th day. The steady-state parameters  $T_{max}$ ,  $C_{max}$ ,  $C_{min}$ ,  $AUC_{0-\infty}$ ,  $C_{avg}$  (calculated as  $AUC_{0-24}/\tau$ ) and FR (fluctuation ratio, calculated as  $(C_{max}-C_{min})/C_{avg}$ ) were also estimated during this exercise.

#### Results

[0124] Of the 12 subjects enrolled, 10 completed the study. Two subjects were dropped prior to receiving the reference treatment, therefore their data were not included in the PK analysis.

[0125] Mean plasma pramipexole concentrations over the 48-hour assessment period are shown in Fig. 5. PK estimates derived from the individual subject data are provided in Table 9.

Table 9. PK parameters (mean  $\pm$  standard deviation)

Parameter	IR tablet (Mirapex®)	XR tablets		
		Example 5	Example 6	Example 9
$AUC_{0-\infty}$ (ng.h/ml)	9.93 $\pm$ 3.05	9.05 $\pm$ 3.24	9.66 $\pm$ 2.91	8.91 $\pm$ 4.15
$AUC_{0-48}$ (ng.h/ml)	8.60 $\pm$ 2.63	7.76 $\pm$ 2.83	7.60 $\pm$ 2.00	7.07 $\pm$ 2.77
$C_{\max}$ (ng/ml)	0.433 $\pm$ 0.083 *	0.332 $\pm$ 0.076	0.282 $\pm$ 0.069	0.242 $\pm$ 0.062
$T_{\max}$ (h)	15.9 $\pm$ 3.4 *	6.2 $\pm$ 2.0	12.0 $\pm$ 5.3	15.6 $\pm$ 6.2
$T_{1/2}$ (h)	9.1 $\pm$ 2.6	11.4 $\pm$ 4.1	11.9 $\pm$ 2.8	12.1 $\pm$ 6.0

\* reached after third 0.125 mg tablet

[0126] Mean cumulative absorption data (up to 24 hours) for the XR tablets are shown in Table 10, together with corresponding *in vitro* dissolution data from Example 10.

Table 10. *In vitro* dissolution and *in vivo* absorption data for XR tablets

Time (h)	Example 5		Example 6		Example 9	
	% diss. ( <i>in vitro</i> )	% abs. ( <i>in vivo</i> )	% diss. ( <i>in vitro</i> )	% abs. ( <i>in vivo</i> )	% diss. ( <i>in vitro</i> )	% abs. ( <i>in vivo</i> )
0	0	0.0	0	0.0	0	0.0
1	15	10.6	11	3.3	2	0.0
2	24	21.1	20	13.2	7	0.5
4	36	43.2	34	30.0	20	15.0
6	47	52.3	46	39.4	31	23.9
8	55	57.8	55	45.6	41	29.6
12	69	68.6	70	57.1	56	41.6
16	79	75.5	80	67.4	69	51.1
24	90	83.6	92	83.2	85	64.8

[0127] *In vitro/in vivo* correlation plots derived from the data of Table 7 are shown in Figs. 3-5 for the XR tablets of Examples 1, 2 and 5 respectively.

[0128] Estimated PK parameters calculated from predicted steady-state concentrations are given in Table 11.

Table 11. Estimated steady-state PK parameters (mean  $\pm$  standard deviation)

Parameter	IR tablet (Mirapex®)	XR tablets		
		Example 5	Example 6	Example 9
$T_{\max}$ (h)		5.4 $\pm$ 1.9	5.6 $\pm$ 1.3	8.0 $\pm$ 2.8
$C_{\max}$ (ng/ml)	0.53 $\pm$ 0.13	0.49 $\pm$ 0.15	0.48 $\pm$ 0.14	0.41 $\pm$ 0.14
$C_{\min}$ (ng/ml)	0.29 $\pm$ 0.14	0.22 $\pm$ 0.12	0.27 $\pm$ 0.11	0.25 $\pm$ 0.15
$C_{ave}$ (ng/ml)	0.40 $\pm$ 0.13	0.36 $\pm$ 0.14	0.38 $\pm$ 0.12	0.34 $\pm$ 0.15
$AUC_{0-\infty}$ (ng.h/ml)	9.63 $\pm$ 3.12	8.66 $\pm$ 3.29	9.00 $\pm$ 2.92	8.06 $\pm$ 3.52
FR	0.66 $\pm$ 0.22	0.87 $\pm$ 0.31	0.61 $\pm$ 0.18	0.62 $\pm$ 0.45

[0129] The subjects dropped from the study experienced a non-serious adverse event, orthostatic hypotension. Both subjects were receiving treatment with the XR tablet of Example 1 when this adverse event occurred.

[0130] No serious adverse events were reported in the study. The most frequently reported event was orthostatic hypotension, all but two of which were considered transient in nature. The numbers of individual non-serious adverse events reported for each treatment are given in Table 12.

**Table 12. Numbers of non-serious adverse events reported**

	IR tablet (Mirapex®)	XR tablets		
		Example 5	Example 6	Example 9
No. of subjects	10	12	11	10
All events	9	17	8	5
Orthostatic hypotension	1	5	2	1

Discussion

[0131] The mean plasma pramipexole concentration profile shown in Fig. 5 clearly shows the tablets of Examples 5, 6 and 9 effectively extended the release of pramipexole relative to the IR tablet. The XR tablets of Examples 5 and 6 exhibit a delay of approximately 1 hour in onset of absorption, whereas quantifiable levels of pramipexole were not observed until about 3 hours after administration of the XR tablet of Example 9.

[0132] The derived PK parameters given in Table 9, in particular the  $C_{max}$  and  $T_{max}$  data, indicate that of the XR tablets, the tablet of Example 5 exhibited the fastest and the tablet of Example 9 the slowest absorption, the tablet of Example 6 being intermediate in this regard.

[0133] The relatively high incidence of non-serious adverse events associated with the tablet of Example 5 suggests that the relatively rapid release of pramipexole from this formulation, leading to a relatively high  $C_{max}$ , is detrimental to the safety profile of such a formulation. On the other hand, the tablets of Examples 6 and 9 exhibit a safety profile that is at least as favorable as the IR tablet administered three times daily. As shown in Table 11, the predicted fluctuation ratio was also greatest for the tablet of Example 5. As shown in Figs. 6-8, a strong *in vitro/in vivo* correlation was established within each formulation. Surprisingly, however, the *in vitro* dissolution data did not clearly distinguish the uncoated tablet of Example 5 from the coated tablet of Example 6, except, as pointed out above, at the earliest sampling times.

## WHAT IS CLAIMED IS:

1. A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprising a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about  $0.15 \text{ kN cm}^{-2}$ , preferably at least about  $0.175 \text{ kN cm}^{-2}$ , and more preferably at least about  $0.2 \text{ kN cm}^{-2}$ , at a solid fraction representative of the tablet.
2. The composition of Claim 1 wherein the starch is a pregelatinized starch.
3. The composition of either of Claims 1 or 2 wherein the starch is present in an amount of about 25% to about 75%, preferably about 40% to about 70%, and more preferably about 45% to about 65%, by weight.
4. The composition of any of the preceding claims wherein the hydrophilic polymer is selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, carmelloose sodium and carbomer.
5. The composition of any of the preceding claims wherein the hydrophilic polymer is hydroxypropylmethylcellulose.
6. The composition of any of the preceding claims wherein the hydrophilic polymer is present in an amount of about 20% to about 70%, preferably about 30% to about 60%, and more preferably about 35% to about 50%, by weight.
7. The composition of any of the preceding claims wherein the salt has solubility not less than about 50 mg/ml, preferably not less than about 100 mg/ml.
8. The composition of any of Claims 1 to 6 wherein the salt is pramipexole dihydrochloride.
9. The composition of any of the preceding claims that comprises about 0.1 to about 10 mg, preferably about 0.2 to about 6 mg, and more preferably about 0.3 to about 5 mg, pramipexole per tablet, expressed as pramipexole dihydrochloride monohydrate equivalent.
10. The composition of any of the preceding claims, further comprising a coating on the tablet.
11. The composition of Claim 10 wherein said coating is a release-controlling layer.
12. The composition of Claim 11 wherein said release-controlling layer constitutes

about 1% to about 15% by weight of the tablet.

13. The composition of Claim 10 wherein said coating is a nonfunctional coating.
14. A pharmaceutical composition in a form of an orally deliverable tablet having a core comprising pramipexole dihydrochloride monohydrate in an amount of about 0.375, 0.75, 1.5, 3 or 4.5 mg, dispersed in a matrix comprising (a) HPMC type 2208 in an amount of about 35% to about 50% by weight of the tablet and (b) a pregelatinized starch having a tensile strength of at least about  $0.15 \text{ kN cm}^{-2}$  at a solid fraction of 0.8, in an amount of about 45% to about 65% by weight of the tablet; said core being substantially enclosed in a coating that constitutes about 2% to about 7% of the weight of the tablet, said coating comprising an ethylcellulose-based hydrophobic or water-insoluble component and an HPMC-based pore-forming component in an amount of about 10% to about 40% by weight of the ethylcellulose-based component.
15. A method of treatment of a subject having a condition or disorder for which a dopamine D<sub>2</sub> receptor agonist is indicated, the method comprising orally administering to the subject the pharmaceutical composition of any of the preceding claims.
16. The method of Claim 15 wherein the composition is administered not more than once daily.
17. The method of either of Claims 15 or 16 wherein the condition or disorder is Parkinson's disease or a complication associated therewith.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/23205

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K31/428 A61K9/20 A61K9/28

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 933 079 A (CERESTAR HOLDING BV) 4 August 1999 (1999-08-04) cited in the application examples	1-17
Y	US 6 277 875 B1 (HOLMAN ANDREW J) 21 August 2001 (2001-08-21) column 7, line 32 -column 8, line 57 column 11, line 20 - line 46	1-17
Y	US 4 731 374 A (KOBINGER WALTER ET AL.) 15 March 1988 (1988-03-15) column 7, line 16 -column 9, line 46 examples I, V	1-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*S\* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the International search report
21 November 2003	02/12/2003
Name and mailing address of the ISA  European Patent Office, P.O. Box 8040 Patenttaan 2 NL - 2200 HV Rijswijk Tel: (+31-70) 340-2040, Fax: 31 651 epo nl Fax: (+31-70) 340-3016	Authorized officer  Giménez Miralles, J

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 03/23205

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 16442 A (JU TZU CHI ROBERT ;UPJOHN CO (US)) 8 April 1999 (1999-04-08) page 2, line 4 - line 13 page 2, line 32 - line 36 page 3, line 1 - line 11 page 3, line 20 - line 29 examples 9-11 -----	1-17
Y	WO 00 59477 A (JANS EUGENE MARIE JOZEF ;JANSSEN PHARMACEUTICA NV (BE); VANDECROUYS) 12 October 2000 (2000-10-12) page 1, line 4 - line 12 page 8, line 9 page 10, line 26 -page 13, line 3 page 20, line 21 -page 24, line 19 examples -----	1-17
Y	WO 97 04752 A (DURAMED PHARMACEUTICALS INC) 13 February 1997 (1997-02-13) page 13, line 36 -page 14, line 8 page 15, line 1 -page 16, line 7 page 16, line 34 -page 17, line 29 page 19, line 1 - line 15 example 1 -----	1-17
Y	WO 99 09066 A (CARRIERE FRANCOIS ;DUMOULIN YVES (CA); ROUGIER INC (CA)) 25 February 1999 (1999-02-25) page 11, line 5 - line 18 page 13, line 26 - line 32 examples 28,48,68,88 -----	1-17
Y	US 2002/015735 A1 (NADKARNI SREEKANT ET AL) 7 February 2002 (2002-02-07) paragraph '0332! - paragraph '0349! paragraph '0356! - paragraph '0359! claim 33; examples -----	1-17
Y	US 6 056 977 A (BHAGWAT DILEEP ET AL) 2 May 2000 (2000-05-02) column 11, line 62 -column 12, line 48 examples -----	1-17
Y	US 5 472 712 A (CHASIN MARK ET AL) 5 December 1995 (1995-12-05) column 31, line 56 -column 32, line 9; examples 13,14 examples 22-29 -----	1-17
Y	WO 99 45924 A (ROUSSEAU LAURENCE ;SMITHKLINE BEECHAM PLC (GB); SMITHKLINE BEECHAM) 16 September 1999 (1999-09-16) examples 3-5 -----	1-17
	-----	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/23205

## C./Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2 887 440 A (GREMINER JR GEORGE K ET AL) 19 May 1959 (1959-05-19) the whole document -----	1-17

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/23205

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 15-17  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.: 1-17 partially  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 15-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 15-17

Rule 39.1(iv) PCT ~ Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1-17 partially

Present independent claims 1, 14 and 15 relate to a sustained-release formulation of pramipexole wherein one technical feature (starch) is defined/characterized by reference to an intrinsic property thereof expressed in terms of a parameter, namely: "tensile strength of at least about 0.15 kN cm<sup>-2</sup> at a solid fraction of 0.8". The use of this parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameter the applicant has chosen to employ with what is set out in the prior art, i.a. because this parameter is not described/used in the relevant prior art, and because the values obtained for this parameter depend on the method/conditions of measurement of both tensile strength and solid fraction. The lack of clarity is such as to render a meaningful complete search impossible.

Consequently, the search has been carried out, ignoring said parametric definition, for sustained-release formulations of pramipexole comprising the technical feature "pregelatinized starch", as disclosed in the description in connection with the examples, and in claims 2 and 14.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/23205

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0933079	A	04-08-1999	EP	0933079 A1	04-08-1999
			JP	11269202 A	05-10-1999
			US	6143324 A	07-11-2000
US 6277875	B1	21-08-2001	AU	7191001 A	30-01-2002
			BR	0112476 A	22-07-2003
			CA	2414774 A1	24-01-2002
			CN	1443066 T	17-09-2003
			CZ	20030417 A3	13-08-2003
			EP	1311251 A2	21-05-2003
			HU	0301305 A2	28-08-2003
			NO	20030213 A	11-03-2003
			WO	0205797 A2	24-01-2002
			US	6300365 B1	09-10-2001
US 4731374	A	15-03-1988	DE	3447075 A1	03-07-1986
			DE	3508947 A1	18-09-1986
			AT	45735 T	15-09-1989
			AU	583874 B2	11-05-1989
			AU	5154485 A	17-07-1986
			BG	62023 B2	30-12-1998
			BR	1100678 A3	13-10-1999
			CA	1263653 A1	05-12-1989
			CS	9104099 A3	16-09-1992
			DD	242230 A5	21-01-1987
			DE	3572485 D1	28-09-1989
			DK	590285 A	23-06-1986
			EP	0186087 A1	02-07-1986
			ES	8702787 A1	01-04-1987
			ES	8707513 A1	16-10-1987
			ES	8707514 A1	16-10-1987
			ES	8707515 A1	16-10-1987
			FI	855102 A ,B,	23-06-1986
			GR	853126 A1	22-04-1986
			HK	78692 A	23-10-1992
			HU	39736 A2	29-10-1986
			IE	58863 B1	17-11-1993
			IL	77415 A	19-03-1990
			JP	1854941 C	07-07-1994
			JP	5072907 B	13-10-1993
			JP	61155377 A	15-07-1986
			KR	9309791 B1	11-10-1993
			LU	90208 A9	06-04-1998
			MX	9202792 A1	30-06-1992
			NO	855195 A ,B,	23-06-1986
			NZ	214661 A	26-04-1990
			PH	24533 A	03-08-1990
			PT	81735 A ,B	01-01-1986
			SG	82492 G	04-12-1992
			US	4843086 A	27-06-1989
			US	4886812 A	12-12-1989
			ZA	8509731 A	26-08-1987
WO 9916442	A	08-04-1999	AU	742941 B2	17-01-2002
			AU	9296498 A	23-04-1999
			BR	9812687 A	22-08-2000
			CA	2301869 A1	08-04-1999
			CN	1268890 T	04-10-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/23205

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
WO 9916442	A	EP FI HU JP NO PL RU SK WO US US	1017391 A2 20000720 A 0004586 A2 2001517701 T 20001624 A 339946 A1 2205007 C2 3612000 A3 9916442 A2 6197339 B1 2001053386 A1	12-07-2000 29-03-2000 28-06-2001 09-10-2001 29-03-2000 15-01-2001 27-05-2003 12-09-2000 08-04-1999 06-03-2001 20-12-2001	
WO 0059477	A	12-10-2000	AU BG BR CA CN CZ EE WO EP HR HU JP NO NZ SK	3963800 A 105857 A 0009437 A 2371940 A1 1345233 T 20013375 A3 200100505 A 0059477 A1 1169024 A1 20010700 A1 0200611 A2 2002541090 T 20014724 A 514890 A 13542001 A3	23-10-2000 30-04-2002 15-01-2002 12-10-2000 17-04-2002 15-05-2002 16-12-2002 12-10-2000 09-01-2002 30-04-2003 29-07-2002 03-12-2002 28-09-2001 30-05-2003 06-08-2002
WO 9704752	A	13-02-1997	CA CN EP JP WO WO US	2227887 A1 1197387 A 0840599 A1 2002504069 T 9704752 A1 9704753 A1 5908638 A	13-02-1997 28-10-1998 13-05-1998 05-02-2002 13-02-1997 13-02-1997 01-06-1999
WO 9909066	A	25-02-1999	CA AU WO	2211778 A1 8724198 A 9909066 A1	14-02-1999 08-03-1999 25-02-1999
US 2002015735	A1	07-02-2002	US AU AU BR BR CA CA CN CN CZ EP EP JP JP NO NO SK SK	2003170303 A1 2586801 A 2731401 A 0016629 A 0016705 A 2394222 A1 2394232 A1 1433309 T 1434713 T 20022140 A3 1239857 A1 1239856 A1 2003518061 T 2003518062 T 20022987 A 20022988 A 9022002 A3 9032002 A3	11-09-2003 03-07-2001 03-07-2001 03-09-2002 24-09-2002 28-06-2001 28-06-2001 30-07-2003 06-08-2003 13-11-2002 18-09-2002 18-09-2002 03-06-2003 03-06-2003 21-08-2002 21-08-2002 04-03-2003 04-03-2003

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/23205

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
US 2002015735	A1	WO	0145705 A1	28-06-2001	
		WO	0145706 A1	28-06-2001	
		AU	1930301 A	18-06-2001	
		AU	1931001 A	18-06-2001	
		BG	105873 A	30-04-2002	
		BR	0008059 A	26-03-2002	
		CA	2362816 A1	14-06-2001	
		CN	1379669 T	13-11-2002	
		CZ	20013163 A3	12-06-2002	
		EA	3639 B1	28-08-2003	
		EE	200100414 A	16-12-2002	
		EP	1165072 A2	02-01-2002	
		HR	20010582 A1	31-08-2002	
		HU	0200409 A2	29-06-2002	
		JP	2003516353 T	13-06-2003	
		NO	20013858 A	08-10-2001	
		NZ	513963 A	31-10-2003	
		PL	351069 A1	10-03-2003	
		SK	12692001 A3	04-04-2002	
		TR	200102297 T1	21-03-2002	
		WO	0141761 A2	14-06-2001	
		WO	0141762 A2	14-06-2001	
		US	2002013357 A1	31-01-2002	
US 6056977	A	02-05-2000	AU	1087799 A	03-05-1999
			CA	2306103 A1	22-04-1999
			EP	1028709 A1	23-08-2000
			JP	2001519377 T	23-10-2001
			WO	9918932 A1	22-04-1999
			US	6537578 B1	25-03-2003
US 5472712	A	05-12-1995	US	5273760 A	28-12-1993
			AT	221375 T	15-08-2002
			AU	704524 B2	29-04-1999
			AU	4368797 A	22-01-1998
			AU	680491 B2	31-07-1997
			AU	6484694 A	19-01-1995
			CA	2125904 A1	24-12-1994
			DE	69431089 D1	05-09-2002
			DE	69431089 T2	27-03-2003
			DK	630646 T3	25-11-2002
			EP	1203581 A2	08-05-2002
			EP	0630646 A1	28-12-1994
			ES	2180552 T3	16-02-2003
			FI	943022 A	24-12-1994
			JP	7138189 A	30-05-1995
			NO	942382 A	27-12-1994
			PT	630646 T	31-12-2002
			US	6294195 B1	25-09-2001
			US	2003180361 A1	25-09-2003
			US	5968551 A	19-10-1999
			US	2002081333 A1	27-06-2002
			AT	196079 T	15-09-2000
			AU	652871 B2	08-09-1994
			AU	3002492 A	01-07-1993
			BR	9202982 A	29-06-1993
			CA	2061824 A1	25-06-1993
			DE	69231415 D1	12-10-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/23205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5472712	A	DE 69231415 T2 DK 548448 T3 EG 20083 A EP 0548448 A1 ES 2152221 T3 FI 921548 A GR 3034951 T3 HK 1005686 A1 IE 920795 A1 IL 101080 A JP 3061474 B2 JP 7165609 A KR 252188 B1 MX 9200932 A1 NO 925016 A NZ 241660 A PT 548448 T SG 44703 A1 US 2003054032 A1 US 6316031 B1 US 5958459 A US 5681585 A US 6129933 A	29-03-2001 22-01-2001 31-08-1997 30-06-1993 01-02-2001 25-06-1993 28-02-2001 09-02-2001 30-06-1993 05-12-1996 10-07-2000 27-06-1995 01-05-2000 01-06-1993 25-06-1993 26-05-1993 30-03-2001 19-12-1997 20-03-2003 13-11-2001 28-09-1999 28-10-1997 10-10-2000
WO 9945924	A 16-09-1999	AU 748396 B2 AU 3033299 A CA 2323177 A1 CN 1292696 T WO 9945924 A1 EP 1061918 A1 HU 0101043 A2 JP 2002506031 T NO 20004491 A NZ 505807 A PL 342600 A1 TR 200002626 T2 US 6451343 B1 ZA 9901921 A BR 9908374 A	06-06-2002 27-09-1999 16-09-1999 25-04-2001 16-09-1999 27-12-2000 28-12-2001 26-02-2002 08-09-2000 31-01-2003 18-06-2001 21-03-2001 17-09-2002 11-09-2000 31-10-2000
US 2887440	A 19-05-1959	NONE	